+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030- Product Image
Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030- Product Image
Sale

Pneumococcal Polysaccharide Vaccine Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134352
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The pneumococcal polysaccharide vaccine market is undergoing significant evolution, driven by advances in immunogenic technology, policy updates, and dynamic supply chain restructuring. Senior decision-makers face an increasingly complex environment requiring agile strategies to optimize vaccine access, manage cost pressures, and expand outreach to both established and emerging patient cohorts.

Market Snapshot: Opportunities in the Pneumococcal Polysaccharide Vaccine Market

The pneumococcal polysaccharide vaccine market continues to expand in response to rising awareness of invasive pneumococcal disease risks worldwide. Increasing demand from both adult and pediatric populations is reshaping product strategies and distribution models. As global immunization initiatives emphasize both broader coverage and targeted interventions, market participants are adopting new technologies, investing in local production, and strengthening cross-sector partnerships to address regional and cohort-specific needs.

Scope & Segmentation of the Pneumococcal Polysaccharide Vaccine Market

Comprehensive segmentation helps decision-makers streamline strategies aligned to real-world adoption patterns:

  • End User Types: Ambulatory surgical centers, government clinics, private clinics, public hospitals, private hospitals.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Age Groups: Adults 18–44, adults 45–64, elderly 65–74, elderly 75+, pediatrics 0–2, pediatrics 3–12, pediatrics 13–17.
  • Administration Routes: Intramuscular, subcutaneous.
  • Presentation Forms: Pre-filled syringes, multi-dose vials, single-dose vials.
  • Regions Covered: Americas (including United States by major states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (with key national focus), Asia-Pacific (China, India, Japan, Australia, South Korea, and others).
  • Key Companies: Merck & Co., Inc.; Serum Institute of India Pvt. Ltd.; Panacea Biotec Ltd.; Shantha Biotechnics (Public) Ltd.; Bharat Biotech International Ltd.; Chengdu Institute of Biological Products Co., Ltd.; Beijing Minhai Biotechnology Co., Ltd.; Shanghai Institute of Biological Products Co., Ltd.; Sinovac Biotech Ltd.; Hualan Biological Engineering Inc.

Key Takeaways for Senior Decision-Makers

  • Expanding adult immunization policies are moving the pneumococcal polysaccharide vaccine beyond high-risk groups, increasing its integration in community and outpatient healthcare settings.
  • Breakthroughs in antigen and adjuvant development are strengthening immune responses, supporting longer-lasting and broader protection for diverse populations.
  • Digital health innovations, such as cold chain monitoring and adherence apps, are improving vaccine integrity and compliance while enabling streamlined delivery to remote or underserved regions.
  • Collaborative efforts between governments, industry, and academia accelerate clinical development, supply resilience, and real-time response to fluctuating regional demand.
  • Segmented deployment strategies, based on age, administration route, and facility type, maximize public health impact and ensure efficient resource allocation across multiple patient populations.

Pneumococcal Polysaccharide Vaccine Market: U.S. Tariff Impact

Tariff measures enacted in 2025 in the United States have altered input costs and procurement strategies. Elevated duties on vaccine components, such as specialized polysaccharides and intermediary chemicals, are prompting manufacturers to boost domestic production and revise sourcing models. This shift drives new local partnerships, stimulates investment in domestic capacity, and encourages technology transfer between multinational and regional producers. Collaborative solutions in warehousing and logistics are emerging as key approaches for distributors and procurement agencies to offset rising financial pressures and to protect vaccine accessibility, particularly in budget-constrained health programs.

Methodology & Data Sources

This report utilizes structured interviews with leading immunologists, public health officials, and procurement specialists, combined with a review of peer-reviewed publications, regulatory documents, and clinical trial data. Data triangulation integrates public shipment records with proprietary databases to identify distribution and demand trends, while validation workshops with industry stakeholders ensure practical relevance and analytical rigor.

Why This Report Matters: Actionable Insights for Executives

  • Leverage in-depth segmentation to tailor vaccine strategies for optimal uptake across age cohorts, end-user environments, and distribution channels.
  • Understand how technological investments and regional policies can drive resilient manufacturing and maintain affordability amid supply chain disruptions.
  • Inform key decisions on portfolio expansion, local partnerships, and product differentiation grounded in robust evidence and market intelligence.

Conclusion

Industry stakeholders who align their strategies with evolving immunization guidelines, technological advancements, and shifting policy landscapes will be best positioned for sustainable growth. The report’s insights help decision-makers navigate the complexities of vaccine deployment in a rapidly changing market.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of serotype-specific pneumococcal polysaccharide vaccines tailored to regional epidemiology and high-risk adult cohorts
5.2. Expansion of adult immunization guidelines recommending 23-valent polysaccharide vaccines for seniors and immunocompromised patients
5.3. Development of combination pneumococcal conjugate and polysaccharide formulations to improve immunogenicity in elderly populations
5.4. Cost effectiveness assessments influencing governmental procurement decisions for 23-valent pneumococcal polysaccharide vaccines in emerging markets
5.5. Integration of real-world evidence from surveillance networks into postmarketing studies of pneumococcal polysaccharide vaccine effectiveness and safety
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Pneumococcal Polysaccharide Vaccine Market, by End User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Clinics
8.3.1. Government Clinics
8.3.2. Private Clinics
8.4. Hospitals
8.4.1. Private Hospitals
8.4.2. Public Hospitals
9. Pneumococcal Polysaccharide Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. Pneumococcal Polysaccharide Vaccine Market, by Age Group
10.1. Introduction
10.2. Adults 18-64
10.2.1. 18-44
10.2.2. 45-64
10.3. Elderly 65+
10.3.1. 65-74
10.3.2. 75+
10.4. Pediatrics 0-17
10.4.1. 0-2
10.4.2. 13-17
10.4.3. 3-12
11. Pneumococcal Polysaccharide Vaccine Market, by Administration Route
11.1. Introduction
11.2. Intramuscular
11.3. Subcutaneous
12. Pneumococcal Polysaccharide Vaccine Market, by Presentation
12.1. Introduction
12.2. Pre-Filled Syringes
12.3. Vials
12.3.1. Multi-Dose Vials
12.3.2. Single-Dose Vials
13. Americas Pneumococcal Polysaccharide Vaccine Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Pneumococcal Polysaccharide Vaccine Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Pneumococcal Polysaccharide Vaccine Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Merck & Co., Inc.
16.3.2. Serum Institute of India Pvt. Ltd.
16.3.3. Panacea Biotec Ltd.
16.3.4. Shantha Biotechnics (Public) Ltd.
16.3.5. Bharat Biotech International Ltd.
16.3.6. Chengdu Institute of Biological Products Co., Ltd.
16.3.7. Beijing Minhai Biotechnology Co., Ltd.
16.3.8. Shanghai Institute of Biological Products Co., Ltd.
16.3.9. Sinovac Biotech Ltd.
16.3.10. Hualan Biological Engineering Inc.
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHAI
FIGURE 26. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHSTATISTICS
FIGURE 27. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHCONTACTS
FIGURE 28. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY GOVERNMENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 18-44, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 18-44, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 45-64, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 45-64, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 65-74, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 65-74, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 75+, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 75+, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 0-2, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 0-2, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 13-17, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 13-17, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 3-12, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY 3-12, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRE-FILLED SYRINGES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY MULTI-DOSE VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SINGLE-DOSE VIALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY SINGLE-DOSE VIALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 131. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 134. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 135. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 136. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 137. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 138. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 139. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 142. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 143. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 144. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 145. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 146. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 147. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 148. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 149. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 150. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 151. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 152. CANADA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 153. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 156. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 157. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 162. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 163. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 164. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 165. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 166. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 167. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 168. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 169. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 170. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 171. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 172. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 174. MEXICO PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 246. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 247. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 248. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 265. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 268. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 269. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 274. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 275. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2018-2024 (USD MILLION)
TABLE 276. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADULTS 18-64, 2025-2030 (USD MILLION)
TABLE 277. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2018-2024 (USD MILLION)
TABLE 278. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ELDERLY 65+, 2025-2030 (USD MILLION)
TABLE 279. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2018-2024 (USD MILLION)
TABLE 280. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PEDIATRICS 0-17, 2025-2030 (USD MILLION)
TABLE 281. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 282. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 283. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
TABLE 284. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY PRESENTATION, 2025-2030 (USD MILLION)
TABLE 285. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2018-2024 (USD MILLION)
TABLE 286. GERMANY PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY VIALS, 2025-2030 (USD MILLION)
TABLE 287. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
TABLE 290. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY CLINICS, 2025-2030 (USD MILLION)
TABLE 291. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 292. FRANCE PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE PNEUMOCOCCAL P

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pneumococcal Polysaccharide Vaccine Market report include:
  • Merck & Co., Inc.
  • Serum Institute of India Pvt. Ltd.
  • Panacea Biotec Ltd.
  • Shantha Biotechnics (Public) Ltd.
  • Bharat Biotech International Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Shanghai Institute of Biological Products Co., Ltd.
  • Sinovac Biotech Ltd.
  • Hualan Biological Engineering Inc.

Related Topics

Related Reports

Pneumococcal Vaccine Market - Global Forecast 2025-2030 - Product Image

Pneumococcal Vaccine Market - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Pneumococcal Vaccines - Global Strategic Business Report - Product Image

Pneumococcal Vaccines - Global Strategic Business Report

  • Report
  • 285 Pages
  • Global
From
Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
India Pneumococcal Vaccine Market, By Region, Competition, Forecast & Opportunities, 2020-2030F - Product Image

India Pneumococcal Vaccine Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • Report
  • 85 Pages
  • India
From
Pneumococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Pneumococcal Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the Pneumococcal Polysaccharide Vaccine Market

The Pneumococcal Polysaccharide Vaccine (PPV) is a vaccine used to protect against infections caused by the bacterium Streptococcus pneumoniae. It is recommended for adults over the age of 65, as well as those with certain medical conditions, such as asthma, diabetes, and heart disease. The vaccine is administered as a single injection, and is usually given in combination with other vaccines. It is also recommended for children aged 2-5 years, and for those who are at high risk of developing pneumococcal disease. PPV is a widely used vaccine, and is available in many countries around the world. It is typically administered in combination with other vaccines, such as the influenza vaccine, and is often given in combination with other vaccines in a single injection. The PPV market is highly competitive, with many companies offering the vaccine. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Sanofi Pasteur, Pfizer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.